Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis Karolina StrzebonskaMateusz T. WasylewskiMarcin Waligora Systematic Review Open access 10 June 2021 Pages: 415 - 424
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review Ziran ZhaoYibo GaoJie He Systematic Review 13 May 2021 Pages: 425 - 434
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort Benjamin TanAdnan KhattakNicolas Isambert Original Research Article Open access 19 May 2021 Pages: 435 - 446
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia Chia-Chi LinToshihiko DoiShunsuke Kondo Original Research Article Open access 11 April 2021 Pages: 447 - 459
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies Alexander SpiraAaron R. HansenWalid L. Shaib Original Research Article Open access 03 May 2021 Pages: 461 - 469
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study Adam GoldmanDavid BomzeElad Maor Original Research Article 10 May 2021 Pages: 471 - 483
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study Almudena CallejoSara FaouziAxel Le Cesne Original Research Article 05 June 2021 Pages: 485 - 492
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study Hiroki IshiharaYuki NemotoKazunari Tanabe Original Research Article 26 June 2021 Pages: 493 - 502
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy Sean BujarskiKyle UddJames R. Berenson Original Research Article 07 June 2021 Pages: 503 - 515
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment Pina ZiranuEleonora LaiMario Scartozzi Original Research Article Open access 10 May 2021 Pages: 517 - 527
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy Giovanni FucàTeresa BeninatoMichele Del Vecchio Short Communication 02 June 2021 Pages: 529 - 536